易伟博士,男,2011年,中山大学-法国格勒一大联合培养博士毕业;2011年7月,加入中国科学院上海药物研究所,历任博士后、助理研究员、副研究员、徐华强课题组药物化学部负责人。2016年11月以“高水平研究型”引进人才身份加入kok官网入口,现为kok官网入口特聘教授、中科院青年创新促进会会员、中国药学会会员、中国药理学会会员、中国化学会会员,2015年度赛诺菲·安万特-中国科学院上海生命科学研究院优秀青年科学家奖及2017年广东省杰出青年基金获得者。其主要研究方向为以结构为基础、功能为导向的创新药物设计与发现。至今,易伟博士已在Nature、Cell Res.、ACS Catal.、Org. Lett.、Chem. Commun.等国际权威杂志发表SCI收录研究论文50余篇,其中第一作者及通讯作者近40篇,被引用率超过1500次,H指数为25;申请国内外发明专利10余项-其中,其负责的以GR为靶点的抗炎症、哮喘新药开发项目(PCT专利:WO/2015/048361 A1)已成功实施转让,总金额达5100万余元(人民币);作为负责人或学术骨干承担了多项国家或省部级项目如国家科技部“973”计划、广东省杰出青年基金、国家自然基金重点项目和青年基金、国家博士后基金面上项目及特别资助、上海市自然基金面上项目。目前,其受邀担任多个国际知名杂志如J. Med. Chem., ACS Med. Chem. Lett., Org. Lett., Chem. Commun., Acta Pharmacol. Sin., Eur. J. Med. Chem.等的独立审稿人。
联系邮箱:
yiwei@gzhmu.edu.cn
研究方向:
1) 基于结构的药物设计与发现
2) 基于过渡金属催化C-H活化策略的药物及活性分子导向合成
主要科研项目及成果:
1) 市教育局广医大高水平大学人才引进,B17017005008,2016/11-2021/11,200万,在研,主持
2) 广东省自然科学杰出青年基金,2017A030306031,2017/05-2020/05,100万,在研,主持
3) 中国科学院青年创新促进会会员基金,2016261,2016/01-2019/12,80万元,在研,主持
4) 国家自然科学基金青年项目,81502909,基于结构的新型选择性GR调控剂氢化可的松衍生物的设计、合成及其抗炎机制研究,2016/01-2018/12, 18.5万元, 在研, 主持
5) 赛诺菲?安万特-中国科学院上海生命科学研究院优秀青年人才奖励基金,2015年,6000欧元,药物化学(人才专项经费)
6) 上海市自然基金面上项目,15ZR1447800,新型PPARγ调控剂C2位功能化的VSP-51吲哚衍生物的设计、合成及构效关系研究,2015/01-2017/12, 10万元,在研,主持
7) 中科院药物创新研究院自部署项目,CASIMM0120152031,VSP-51-2作为抗糖尿病先导化合物开发,2015/08-2016/08, 100万, 已结题, 学术骨干(任务一负责人,30万)
8) 国家基金委重大研究计划-集成项目,91217311,独脚金内酯信号传导机制研究、2013/01-2015/12, 280万元,已结题,学术骨干 (负责独脚金内酯类似物设计与合成)
9) 中国博士后科学基金特别资助,2013T60477,以葵酸调节PPARγ新机制为基础的抗糖尿病药物发现,2013/01-2014/12,15万元,已结题,主持
10) 中国博士后科学基金面上资助,2012M511158,氢化可的松衍生物的设计、合成及抗炎活性评估,2012/01-2013/12,5万元,已结题,主持
所获荣誉和奖励:
1) 2017年广东省杰出青年基金获得者
2) 2016年中国科学院青年创新促进会会员
3) 2015年赛诺菲?安万特-中国科学院上海生命科学研究院优秀青年人才奖
主要论文及著作:
u 全职加入kok官网入口后发表代表性论文:
1) X. Xu, R. Sun, S. Zhang, X. Zhang* and W. Yi*. Divergent Synthesis of Quinolones and Dihydroepindolidiones via Cu(I)-Catalyzed Cyclization of Anilines with Alkynes. Org Lett.,2018, DOI: 10.1021/acs.orglett.8b00436. (IF = 6.579,一区)
2) W. Wu#, Y. Guo#, F. X. Xu#, Z. Zhou, X. Zhang*, B. Wu* and W. Yi*. One-pot regioselective synthesis of 2,4-disubstituted quinolines via copper(II)-catalyzed cascade annulation. Org. Chem. Front., 2018, DOI: 10.1039/C8QO00052B. (IF = 4.955,二区)
3) W. Gong#, Z.Zhou#, J. Shi#, B. Wu, B. Huang and W. Yi*. Catalyst-Controlled [3 + 2] and [4 + 2] Annulations of Oximes with Propargyl Alcohols: Divergent Access to Indenamines and Isoquinolines. Org. Lett., 2018, 20, 182-185. (IF = 6.579,一区)
4) X. Xu, Y. Yang, X. Zhang* and W. Yi*. Direct Synthesis of Quinolines via Co(III)-Catalyzed and DMSOInvolved C?H Activation/Cyclization of Anilines with Alkynes. Org. Lett., 2018, 20, 566-569. (IF = 6.579,一区)
5) S. Song, A. You, Z. Chen*, G. Zhu, H. Wen, H. Song* and W. Yi*. Study on the design, synthesis and structure-activity relationships of new thiosemicarbazone compounds as tyrosinase inhibitors. Eur. J. Med. Chem., 2017, 139, 815-825. (IF = 4.519,二区)
6) W. Yi*,#, J. Shi#, G. Zhao#, X. E. Zhou, K. Suino-Powell, K. Melcher and H. E. Xu*. Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro. Sci. Rep., 2017, 7, 41487. (IF = 4.257,二区)
7) X. Xu, Y. Yang, X. Chen, X. Zhang* and W. Yi*. The one-pot synthesis of quinolines via Co(III)-catalyzed C–H activation/carbonylation/cyclization of anilines. Org. Biomol. Chem., 2017, 15, 9061-9065. (IF = 3.564,二区)
8) H. Lv#, J. Shi#, B. Wu, Y. Guo, J. Huang and W. Yi. One-pot synthesis of 2,3-difunctionalized indoles via Rh(III)-catalyzed carbenoid insertion C–H activation/cyclization. Org. Biomol. Chem., 2017, 15, 8054-8058. (IF = 3.564,二区)
9) H. Lv#, J. Shi#, J. Huang, C. Zhang and W. Yi. Rhodium(III)-catalyzed and MeOH-involved regioselective mono-alkenylation of N-arylureas with acrylates. Org. Biomol. Chem.,2017,15, 7088-7092. (IF = 3.564,二区)
u 以前代表性论文:
1) C. Chen#, J. Ke#, X. E. Zhou, W. Yi, et al. Structural basis for molecular recognition of folic acid by folate receptors. Nature, 2013, 500, 486-9. (IF = 40.137,一区)
2) L. Jiang#, X. Liu#, G. Xiong#, H. Liu#, F. Chen, L. Wang, X. Meng, G. Liu, H. Yu, Y. Yuan, W. Yi, et al. DWARF 53 acts as a repressor of strigolactone signaling in rice.Nature, 2013, 504, 401-5. (IF = 40.137, 一区)
3) L.-H. Zhao#, X. E. Zhou#, W. Yi#, et al. Destabilization of strigolactone receptor DWARF14 by binding of ligand and E3-ligase signaling effector DWARF3. Cell Res., 2015, 25, 1219-36. (IF = 14.812, 一区)
4) Y. He*, W. Yi*, et al. Structures and mechanism for the design of highly potent glucocorticoids. Cell Res., 2014, 24, 713-726. (IF = 14.812,一区)
5) J. Zhou, J. Shi, Z. Qi, X. Li*, H. E. Xu and W. Yi*. Mild and efficient Ir(III)-catalyzed direct C-H alkynylation of N-phenoxyacetamides with terminal alkyne.ACS Catal., 2015, 5, 6999-7003. (IF = 10.614,一区)
6) X. Zhang*, Z. Wang, K. Xu, Y. Feng, W. Zhao, X. Xu, Y. Yan and W. Yi*. HOTf-catalyzed sustainable one-pot synthesis of benzene and pyridine derivatives under solvent-free conditions. Green Chem., 2016, 18, 2313-2316. (IF = 9.125,一区)
7) X. Zhang, X. Xu, G. Chen and W. Yi*. Regioselective Synthesis of 2,3,4-Trisubstituted Pyrroles via Pd(II)-Catalyzed Three-Component Cascade Reactions of Amines, Alkyne Esters, and Alkenes. Org Lett., 2016, 18, 4864-4867. (IF = 6.579,一区)
8) J. Shi, J. Zhou, Y. Yan, J. Jia, X. Liu, H. Song, H. E. Xu* and W. Yi*. One-pot cascade synthesis of N-methoxyisoquinolinediones via Rh(III)-catalyzed carbenoid insertion C–H activation/cyclization. Chem. Commun., 2015, 51, 668-671. (IF = 6.32,一区)
9) J. Jia, J. Shi, J. Zhou, X. Liu, Y. Song, H. E. Xu* and W. Yi*. Rhodium(III)-catalyzed C–H activation and intermolecular annulation with terminal alkynes: from indoles to carbazoles. Chem. Commun., 2015, 51, 2925-2928. (IF = 6.32,一区)
10) J. Zhou, J. Shi, X. Liu, J. Jia, H. Song, H. E. Xu* and W. Yi*. Rh(III)-catalyzed and alcohol-involved carbenoid C–H insertion into N-phenoxyacetamides using α-diazomalonates. Chem. Commun., 2015, 51, 5868-5871. (IF = 6.32,一区)
11) J. Shi, Y. Yan, Q. Li, H. E. Xu* and W. Yi*. Rhodium(III)-catalyzed C2-selective carbenoid functionalization and subsequent C7-alkenylation of indoles. Chem. Commun.,2014, 50, 6483-6486. (IF = 6.32,一区)